Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Australian Clinical Labs Ltd ( (AU:ACL) ) has provided an update.
Franklin Resources and its affiliates have reduced their substantial shareholding in Australian Clinical Labs, with their voting interest declining from 5.02% to 4.93% of the company’s ordinary shares. The change reflects a modest decrease in Franklin’s stake, which may slightly lessen its influence among the company’s institutional investor base without materially altering overall control dynamics.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.20 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Limited operates in the healthcare diagnostics industry, providing pathology and laboratory testing services across Australia. The company focuses on clinical testing for healthcare providers, hospitals and patients, supporting medical diagnosis and treatment decisions in the Australian market.
Average Trading Volume: 856,761
Technical Sentiment Signal: Sell
Current Market Cap: A$358.5M
Find detailed analytics on ACL stock on TipRanks’ Stock Analysis page.